Semus Wealth Partners LLC Has $1.15 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Semus Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 13.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,976 shares of the company’s stock after acquiring an additional 231 shares during the period. Eli Lilly and Company accounts for 0.9% of Semus Wealth Partners LLC’s portfolio, making the stock its 21st largest position. Semus Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $1,152,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Leavell Investment Management Inc. grew its holdings in shares of Eli Lilly and Company by 3.2% in the 4th quarter. Leavell Investment Management Inc. now owns 5,726 shares of the company’s stock valued at $3,338,000 after buying an additional 176 shares during the period. Camelot Portfolios LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $870,000. GAM Holding AG grew its holdings in shares of Eli Lilly and Company by 5.9% in the 4th quarter. GAM Holding AG now owns 15,046 shares of the company’s stock valued at $8,771,000 after buying an additional 833 shares during the period. Indiana Trust & Investment Management CO grew its holdings in shares of Eli Lilly and Company by 5.3% in the 4th quarter. Indiana Trust & Investment Management CO now owns 15,500 shares of the company’s stock valued at $9,035,000 after buying an additional 780 shares during the period. Finally, Ballentine Partners LLC grew its holdings in shares of Eli Lilly and Company by 8.4% in the 4th quarter. Ballentine Partners LLC now owns 13,793 shares of the company’s stock valued at $8,040,000 after buying an additional 1,069 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of the company’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the transaction, the insider now owns 99,754,422 shares in the company, valued at approximately $62,873,217,098.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 195,055 shares of company stock worth $125,254,657. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on LLY shares. Bank of America boosted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $700.00.

View Our Latest Report on LLY

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $12.35 on Wednesday, reaching $776.31. The stock had a trading volume of 3,041,599 shares, compared to its average volume of 3,218,342. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm’s 50-day moving average is $742.32 and its two-hundred day moving average is $642.33. The firm has a market capitalization of $737.62 billion, a price-to-earnings ratio of 133.85, a P/E/G ratio of 1.67 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $351.27 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the firm earned $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, research analysts expect that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.